



SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Group")

Result of Annual General Meeting

29 December 2025 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), a life science company focused on skin health, held its Annual General Meeting today and all resolutions were passed.

Resolution	Votes For		Votes Against		Votes Withheld
1. To receive the annual report and accounts	88,024,558	83.50%	17,391,981	16.50%	722,198
2. To re-appoint Gravita as auditor	96,998,314	92.15%	8,266,920	7.85%	873,503
3. To authorise Directors to determine Auditors remuneration	97,093,358	92.13%	8,296,876	7.87%	748,503
4. To authorise the Directors to allot relevant securities	85,828,638	80.90%	20,268,099	19.10%	42,000
5. To authorise the Directors to allot equity securities for cash without a pre-emptive offer to shareholders	85,771,888	80.84%	20,324,849	19.16%	42,000
6. To authorise the Directors to allot equity securities for cash in relation to an acquisition of other capital investment	85,782,499	81.34%	19,682,546	18.66%	673,692

An electronic copy of the Annual Report and Accounts is available and the results of the AGM will be available on the Company's website in due course at www.skinbiotherapeutics.com/investor-relations.

-Ends-

For more information please contact:

SkinBioTherapeutics plc

+44 (0) 191 495 7325

Stuart J. Ashman, CEO
Emily Bertram, Group Finance Director

Singer Capital Markets (Nominated Adviser & Broker)

+44 (0) 020 7496 3000

Philip Davies
Andrew Johnson
James Todd

Vigo Consulting (financial press)

+44 (0) 20 7390 0230

Rozi Morris, Melanie Toyne-Sewell

SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix[®], is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix[®]) and food supplements that harness the gut-skin

axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGPKCBBNBDDPB